Atossa Therapeutics Inc. (ATOS)
0.92
-0.02 (-2.01%)
At close: Jan 24, 2025, 3:59 PM
0.95
3.29%
After-hours Jan 24, 2025, 07:58 PM EST
undefined% (undefined)
| Bid | 0.91 |
| Market Cap | 116.29M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.21 |
| PE Ratio (ttm) | -4.4 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.95 |
| Volume | 453,080 |
| Avg. Volume (20D) | 853,050 |
| Open | 0.93 |
| Previous Close | 0.94 |
| Day's Range | 0.91 - 0.97 |
| 52-Week Range | 0.80 - 2.31 |
| Beta | undefined |
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patien...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2012
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ATOS
Analyst Forecast
According to 3 analyst ratings, the average rating for ATOS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 657.25% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
10 months ago
+20.16%
Atossa Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
